BEDMINSTER, N.J., and DUBLIN, Ireland, Feb. 4, 2014 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that industry veteran, Aaron Berg, has been promoted to Senior Vice President, Marketing and Sales.
With more than 25 years of industry experience, Mr. Berg has significant marketing and sales experience, including six years at Kos Pharmaceuticals where as Vice President of Marketing and Sales his contributions to the commercial success of Niaspan® helped lead to the acquisition of Kos in 2006 by Abbott Laboratories for $3.6 billion. Before joining Kos Pharmaceuticals, Mr. Berg began his pharmaceutical industry career as a sales representative with Bristol-Myers Squibb followed by 10 years of increasing commercial responsibility at Schering-Plough before being recruited by GlaxoSmithKline to help build its then newly launched diabetes franchise. After Kos Pharmaceuticals, Mr. Berg's commercial and business development expertise in lipid therapy led Essentialis, a development-stage company focused on triglyceride management, to appoint Mr. Berg as President and CEO where he remained until he was recruited by Amarin at the end of 2012. Mr. Berg joined Amarin as Vice President, Marketing and Managed Care, which responsibilities he assumed from the time of launch of Vascepa® in early 2013.
"On behalf of Amarin and its Board of Directors, it is with great pleasure that I announce the promotion of Aaron to this important expanded role," stated John F. Thero, President and Chief Executive Officer of Amarin. "Aaron's experience, leadership and dedication since joining Amarin have been crucial factors in establishing the sales focus, product messaging and managed care wins that position Vascepa for further growth. I have the utmost confidence in Aaron's ability to build on these efforts in leading Amarin's commercial team positively forward in its second year of Vascepa commercialization."
"I am proud to be a member of the Amarin team and confident in the continued growth of Vascepa sales," said Mr. Berg. "Vascepa provides physicians and their patients with a valuable offering for the treatment of severe hypertriglyceridemia. It is an exciting time to be at Amarin."
About Vascepa® (icosapent ethyl) capsules
Vascepa® (icosapent ethyl) capsules, known in scientific literature as AMR101, is a highly pure-EPA omega-3 prescription product in a 1 gram capsule.
Indications and Usage
Vascepa (icosapent ethyl) is indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia.
The effect of Vascepa on the risk for pancreatitis and cardiovascular mortality and morbidity in patients with severe hypertriglyceridemia has not been determined.
Important Safety Information for Vascepa
Vascepa is contraindicated in patients with known hypersensitivity (e.g., anaphylactic reaction) to Vascepa or any of its components and should be used with caution in patients with known hypersensitivity to fish and/or shellfish.
The most common reported adverse reaction (incidence > 2% and greater than placebo) was arthralgia (2.3% for Vascepa, 1.0% for placebo).
FULL VASCEPA PRESCRIBING INFORMATION CAN BE FOUND AT WWW.VASCEPA.COM.
Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. Amarin's product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. Vascepa® (icosapent ethyl), Amarin's first FDA approved product, is a patented, ultra pure omega-3 fatty acid product comprising not less than 96% EPA. For more information about Vascepa visit www.vascepa.com. For more information about Amarin visit www.amarincorp.com.
This press release contains forward-looking statements, including statements about Amarin's expectations for commercial growth. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. In particular, as disclosed in its previous filings with the U.S. Securities and Exchange Commission, Amarin's ability to effectively commercialize Vascepa will depend in part on its ability to create market demand for Vascepa through education, marketing and sales activities, to achieve market acceptance of Vascepa, to receive adequate levels of reimbursement from third-party payers, to develop and maintain a consistent source of commercial supply at a competitive price, and to obtain and maintain patent protection and regulatory exclusivity. A further list and description of these risks, uncertainties and other risks associated with an investment in Amarin can be found in Amarin's filings with the U.S. Securities and Exchange Commission, including its most recent Quarterly Report on Form 10-Q. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Amarin undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.
Availability of other information about Amarin
Investors and others should note that we communicate with our investors and the public using our company website (www.amarincorp.com), our investor relations website (http://www.amarincorp.com/investor-splash.html), including but not limited to investor presentations and investor FAQs, Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that we post on these channels and websites could be deemed to be material information. As a result, we encourage investors, the media, and others interested in Amarin to review the information that we post on these channels, including our investor relations website, on a regular basis. This list of channels may be updated from time to time on our investor relations website and may include social media channels. The contents of our website or these channels, or any other website that may be accessed from our website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.
Niaspan® is trademark of AbbVie Inc.
CONTACT: Joseph Bruno
Investor Relations and Corporate Communications
In U.S.: +1 (908) 719-1315
Source: Amarin Corporation plc